Annual Masterclass 2020
The MPE Annual General Meeting (AGM) 2020 was cancelled due to the COVID-19 outbreak. The educational programme planned to be held in the Annual Masterclass was replace the MPE Webinars series.


MPE AGM 2020 - Webinar on Myeloma and AL amyloidosis treatment updates

MPE AGM 2020 - Webinar on reimbursement and Health Technology Assessment (HTA) in Europe

MPE AGM2020 webinar series - Big data, the Harmony example

Watch the webinar on personalised medicines in myeloma and AL amyloidosis

Minimal Residual Disease (MRD) in myeloma and related diseases

Webinar on the impact of myeloma and AL amyloidosis in carers

Annual Masterclass 2019


MPE AGM 2019 outtakes

Myeloma Treatment Updates

Surrogate end-points in myeloma and AL amyloidosis

Measuring and utilising quality of life

AL Amyloidosis

The role of CAR-T

Annual Masterclass 2018


MPE Capacity Building Programme

Community Advisory Boards and case studies of MPE member groups

Rehabilitation, self-care and quality of life

Journey to a professional and empowered advocate

Clinical trials design and study endpoints

Myeloma related diseases

Drug access and affordability

Coping with a chronic disease

Update on diagnosis and treatment of AL amyloidosis

Annual Masterclass 2017


MPE dialogues - “Where are we now in myeloma and how does the future look like?”

Welcome, introductions and driving throught the conference

The European Atlas of Access to Myeloma Treatment

Update on current diagnosis and treatment of myeloma and related diseases

Clinical trials and drugs under development in myeloma and AL Amyloidosis

Treatment of myeloma in the light of access barriers

Patient advocate development strategies: how can an umbrella organisation help you

Annual Masterclass 2016


Treating myeloma. An update on the current myeloma treatment guidelines

Myeloma and Amyloidosis 101

What is multiple myeloma associated amyloidosis?

Advocacy session 1 – Patient involvement in clinical research

Welcome and introductions

The MPE Atlas: myeloma UK case study

Evidence based advocacy: implementing the MPE Atlas

Atlas Coaching Programme

Myeloma beyond C.R.A.B. An update on the current mueloma diagnosis guidelines
